These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16538787)

  • 1. Scintigraphy predicts success of hormone therapy.
    Gould P
    Lancet Oncol; 2006 Mar; 7(3):202. PubMed ID: 16538787
    [No Abstract]   [Full Text] [Related]  

  • 2. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTc-depreotide scintigraphy.
    Van Den Bossche B; Van Belle S; De Winter F; Signore A; Van de Wiele C
    J Nucl Med; 2006 Jan; 47(1):6-13. PubMed ID: 16391181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
    Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
    Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Somatostatin in breast cancer].
    Frati A; Antoine M; Rodenas A; Gligorov J; Rouzier R; Chéreau E
    Ann Biol Clin (Paris); 2011; 69(4):385-91. PubMed ID: 21896402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
    Mackey JR
    J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential role of somatostatin analogues in breast cancer treatment.
    Pollak M
    Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin receptors and breast cancer.
    Cameron Smith M; Orlando C; Serio M; Maggi M
    J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.
    Mullooly M; Pfeiffer RM; Nyante SJ; Heckman-Stoddard BM; Perloff M; Jatoi I; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Berrington de Gonzalez A; Sherman ME; Gierach GL
    J Clin Oncol; 2016 Jun; 34(18):2093-7. PubMed ID: 27022110
    [No Abstract]   [Full Text] [Related]  

  • 10. [Neuroendocrine carcinoma of the breast. Our experience and a proposal of a therapeutic algorithm for a rare tumor].
    Scaramuzzi G; Murgo RM; Cuttitta A; Ciuffreda L
    G Chir; 2008 May; 29(5):203-6. PubMed ID: 18507954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tamoxifen in hospice: pros and cons.
    Herndon CM; Arayath J; Hallin P
    Am J Hosp Palliat Care; 2001; 18(2):133-4. PubMed ID: 11407130
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toremifene citrate (Fareston).
    Gerken P
    Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
    [No Abstract]   [Full Text] [Related]  

  • 14. Tc-99m depreotide scintigraphy of breast carcinoma.
    Montilla-Soler JL; Bridwell RS
    Clin Nucl Med; 2002 Mar; 27(3):202-4. PubMed ID: 11852309
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomic predictor of survival after chemotherapy for breast cancer.
    Burke HB
    JAMA; 2011 Aug; 306(7):708; author reply 708-9. PubMed ID: 21846850
    [No Abstract]   [Full Text] [Related]  

  • 16. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2/neu serum levels vis-à-vis hormonal response in metastatic breast cancer.
    Panasci LC
    J Clin Oncol; 2002 Aug; 20(15):3357; author reply 3357. PubMed ID: 12149314
    [No Abstract]   [Full Text] [Related]  

  • 18. Accumulation of Tc-99m depreotide (NeoSpect) in axillary sweat glands.
    Danielsson R; Bååth M; Kölbeck KG; Klominek J; Svensson L
    Clin Nucl Med; 2003 Sep; 28(9):789-90. PubMed ID: 12973013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
    Jansen MP; Foekens JA; Klijn JG; Berns EM
    J Natl Cancer Inst; 2005 Dec; 97(24):1851-2; author reply 1852-3. PubMed ID: 16368948
    [No Abstract]   [Full Text] [Related]  

  • 20. Tamoxifen for patients with estrogen receptor-negative breast cancer.
    Swain SM
    J Clin Oncol; 2001 Sep; 19(18 Suppl):93S-97S. PubMed ID: 11560981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.